🇺🇸 FDA
Pipeline program

AZD8205, PACLITAXEL, DOXORUBICIN

D6900C00003

Phase 3 small_molecule active

Quick answer

AZD8205, PACLITAXEL, DOXORUBICIN for B7-H4-Selected Advanced/Metastatic Endometrial Cancer. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials